0001104659-24-010262.txt : 20240202
0001104659-24-010262.hdr.sgml : 20240202
20240202200514
ACCESSION NUMBER: 0001104659-24-010262
CONFORMED SUBMISSION TYPE: 5
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231231
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oliviero James F III
CENTRAL INDEX KEY: 0001434718
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 5
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38128
FILM NUMBER: 24593574
MAIL ADDRESS:
STREET 1: C/O KERYX BIOPHARMACEUTICALS, INC.
STREET 2: 750 LEXINGTON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc.
CENTRAL INDEX KEY: 0001651407
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 472568632
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 95 SAWYER ROAD
STREET 2: SUITE 110
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 781-652-4500
MAIL ADDRESS:
STREET 1: 95 SAWYER ROAD
STREET 2: SUITE 110
CITY: WALTHAM
STATE: MA
ZIP: 02453
5
1
tm245141-3_5seq1.xml
OWNERSHIP DOCUMENT
X0508
5
2023-12-31
0
0
1
0001651407
Checkpoint Therapeutics, Inc.
CKPT
0001434718
Oliviero James F III
95 SAWYER RD, SUITE 110
WALTHAM
MA
02453
1
1
0
0
CEO, President and Director
0
Common Stock
2023-02-24
5
G
0
42000
0
D
381580
D
Common Stock
2023-08-16
4
G
0
L
12510
0
D
381580
D
On February 24, 2023, 42,000 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust.
Includes shares of restricted common stock, which vest over various time periods.
On August 16, 2023, 12,510 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust.
/s/ James F. Oliviero, III
2024-02-02